jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
Journal of Young PharmacistsNOW IN
Review

Fruit Flies: From Model Organism to Medical Marvel in Pharmaceutical Research

Yaga Maheswar Reddy1, Chinthaginjala Haranath1★, Dasari Bhargavi1, Gogula Priya1, Subramanyam Nikhila1, Uppara Sruthi1, Tadipatri Shaik Tasleem1, Kamisetty Veekshana1★ Corresponding author

  1. 1Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research (RIPER)-Autonomous, Ananthapuramu, Andhra Pradesh, INDIA.

CORRESPONDENCE

Chinthaginjala Haranath

Professor and Head, Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) Autonomous, Ananthapuramu, 515721, Andhra Pradesh, INDIA.

haranathriper@gmail.com

Received: 22-12-2025; Revised: 13-01-2026; Accepted: 02-03-2026.

Volume 18, Issue 1 · pp. 39–45 · PUBLISHED Jan-Mar 2026 · DOI: 10.5530/jyp.20260297

View on JYP original site ↗

ABSTRACT

Fruit fly, or Drosophila melanogaster, is becoming a cornerstone model organism for biomedical research as a result of its genetic tractability, affordability, and high conservation of genetic pathways with humans. Drosophila has developed from a classical genetics model to a robust system for research into human diseases and drug discovery. The small body size, brief life cycle, and high reproductive rates of the fruit fly render it a suitable organism for big-scale, high-throughput researches. Around 75% of disease-causing genes in humans have functional homologues in drosophila, enabling scientists to explore a broad range of diseases such as neurodegenerative disorders, cancers, epilepsy, metabolic syndromes, cardiovascular diseases, and infectious diseases. It’s completely sequenced genome, along with sophisticated genetic manipulative tools like CRISPR, RNAi, and transgenic technologies, enables specific gene manipulation. Behavioral and physiological tests from memory assays to seizure susceptibility allow functional in vivo studies. Drug discovery applications are broad, with routes of administration from feeding to inhalation and injection. Fly models have been employed in assessing drug efficacy, screening new compounds, and delineating pharmacogenetic heterogeneity. Technological innovations now allow seamless integration with human genotype-phenotype databases, making drosophila more useful in translational research. In addition, the model has helped in the discovery of novel targets for treatments and evaluating toxicity and environment impact. Drosophila melanogaster remains a vital tool in deciphering disease mechanisms and the design of new therapeutic intervention. This review provides the overview and applications of fruit flies in various diseases.

KEYWORDS

0% READ

FULL TEXT

INTRODUCTION

Genetics and bio-medicine research have long relied largely on the fruit fly, Drosophila melanogaster (Atoki et al., 2025). From a simple genetic model to a powerful tool for the investigation of human disease, drosophila has evolved further (Verheyen, 2022). Its application is not limited to classical genetics but extends to developmental biology, neuroscience, and, more recently, disease modeling and drug discovery. Genes conserved in humans are surprisingly common in the drosophila genome, which consists of four chromosomes and 180 megabases (Loesche et al., 2021). Drosophila is a valuable model for investigating a multitude of diseases, from metabolic syndrome and viral infections to neurodegenerative and cancer, since it contains functional homologs of more than 75% of human disease-causing genes (Obafemi et al., 2025).

The organism's entire genome has been sequenced, and a myriad of genetic tools have been developed to specifically manipulate and study gene expression. In addition, drosophila is an ideal model for understanding complex biological mechanisms due to its comparatively simple body plan, which allows extensive phenotypic analyses. In early biomedical research, drosophila is one of the ethical alternatives to vertebrate models due to the increased focus on the 3R principles-Replacement, Reduction, and Refinement (Kratsios et al., 2024). Reduction refers to the strategy of examining the experimental design to ensure that the number of experimental animals utilized in a study has been reduced to the minimum requirement to achieve sufficient results. Replacement refers to measures that replace or avoid the use of experimental animals altogether (Vashishat et al., 2024). Refinement refers to process improvements that minimize the adverse effects of the proposed studies on the involved animals, e.g., decreasing pain, suffering, and distress in a manner that encourages overall animal welfare (Madden et al., 2020). Through their roles as in vivo models for the study of disease biology and evaluation of pharmacologic interventions, model organisms remain a critical component of pre-clinical drug discovery. A shift towards more simple and ethically acceptable models has been prompted by growing concern with animal rights and welfare.

SPECIES OVERVIEW

Generally referred to as the fruit fly or vinegar fly, Drosophila melanogaster is a dipteran fly within the family of Drosophilidae. Drosophila neurogenetic models have served to elucidate the mechanisms behind brain development and synaptic transmission (Duhart et al., 2022). Further, it is an excellent model with which to explore signaling pathways conserved in humans and commonly associated with disease, such as Notch, Hedgehog, and Wnt. Drosophila is an excellent choice for high-throughput research because of its small size and minimal laboratory needs (Kumar et al., 2021). Its tractability in genetics also allows for the development of transgenic lines and RNAi knockdowns to analyze gene function in vivo. Most significantly, genes like Toll-like receptors (Tl), homeobox, dunce (dnc), and period (per) were first discovered in drosophila and subsequently known to have homologs in humans. Fruit fly is an ideal organism to study gene function, interactions, and disease causation owing to its relevance (Yusuf et al., 2022).

ADVANTAGES

Genetic Simplicity and Manipulability

Drosophila differs from other model organisms in that both loss-of-function and gain-of-function tests are simple to conduct. As accurate genetic alterations are provided by CRISPR and transgenic technologies, RNA interference (RNAi) enables precise silencing of genes (Li et al., 2020).

Speed and Cost-Effective Breeding

Flies are readily cultured in the laboratory, requiring little space. Compared to vertebrate models like rats and mice, they are also less expensive to maintain and hence allow large-scale and high-throughput research.

Advanced Behavioral and Physiological Assays

Drosophila is an organism that has simple behavioral and physiological responses. For evaluating learning and memory, motor function, response to pain, and even aggression, assays have been established (Sarkar et al., 2023).

Versatility in Disease Modeling

A large variety of human diseases have drosophila models. These include metabolic conditions (obesity, diabetes), cardiovascular and infectious diseases, neurological diseases (such as Alzheimer's, Parkinson's, and Huntington's), and various cancers.

PATHOPHYSIOLOGICAL RELEVANCE

Due to the strong path route conservation of genes in flies compared to human beings, Drosophila melanogaster is an appropriate model to model human diseases. Drosophila is applied in cancer research to describe the functions of tumor suppressor and oncogene genes (Yamamura et al., 2021). Neurodegenerative diseases such as Huntington's, Parkinson's, and Alzheimer's have been illuminated using Drosophila models in neuroscience. Transgenic flies with human disease genes reproduce the key clinical features, allowing for functional study and drug screening. Using seizure-sensitive mutants that respond to drug therapies similar to those in humans, the model has also significantly informed us about epilepsy. The Toll and Imd routes in flies report on inflammatory and infectious diseases by simulating innate immune responses in mammals (Fischer et al., 2023).

APPLICATIONS

Neurodegenerative diseases

Drosophila has played a major role in helping us understand the molecular origins of neurodegeneration. Human disease genes have been expressed in flies to imitate a variety of illnesses, including Huntington's, Parkinson's, and Alzheimer's (Kashyap et al., 2023). These models often exhibit traits like motor impairment, protein aggregation, and neuron death. Toxic protein aggregation is frequently observed in these models. For example, flies with neurodegeneration caused by the polyglutamine-expanded huntingtin protein can be saved by drugs that block Histone Deacetylase (HDAC). This increases the likelihood of therapeutic potential and permits in vivo drug screening. Figure 1 highlights the importance of drosophila in neurodegenerative diseases.

Figure 1: Application of Drosophila in Neurodegenerative diseases.

Drug discovery

The utility of Drosophila melanogaster in drug development continues to expand and its ability to adapt for high-throughput screening, genetic manipulation, and in vivo phenotypic study. Potential therapeutic chemicals for a variety of illnesses, such as cancer, epilepsy, diabetes, and neurodegenerative disorders, are screened for using drosophila models (Lopez-Ortiz et al., 2023). The effectiveness of anti-epileptic pharmaceuticals, for instance, has been evaluated using seizure-prone fly mutants such as eas2F and parabss1, which exhibit dose-dependent reactions to different anti-seizure treatments. Flies have also been used to model pharmacogenetic variability and medication resistance, which can help identify new therapeutic targets (Fischer et al., 2024). Drosophila is a useful model for early-stage drug discovery because of its low cost, ease of maintenance, and less ethical considerations. The translational potential of this system can be seen by the success of a MEN2 thyroid cancer medication that was developed using a drosophila model.

Cancer research

The majority of human oncogenes and tumor suppressor genes, including Ras, p53, and PTEN, have homo-logs in fruit flies (Lappalainen et al., 2021). By modifying these genes in genetically modified flies, scientists may create tumors and track the resulting phenotypes. For instance, the molecular changes observed in human malignancies appear in drosophila by over activation of cell proliferation pathways and abnormalities in epithelial integrity (Munnik et al., 2022). Drosophila speeds up the process of finding potential medications and treatment targets for cancer research. shares human tumor suppressor genes and conserved oncogenes (Figure 2). Drosophila tumorigenesis is a genetic and cellular model of human cancer development (Nainu et al., 2023).

Figure 2: Role of Drosophila in Cancer Research.

Neurological disorders[Epilepsy]

Drosophila melanogaster provides a genetically tractable model for researching seizure causes and discovering Anti-Seizure Drugs (ASMs) in the field of epilepsy research. Fly models that resemble human epileptic phenotypes, such as bang-sensitive mutants (e.g., eas2F, parabss1), exhibit seizure-like behaviors in response to mechanical stimuli (Yamamoto et al., 2024). These include initial convulsions, transient paralysis, and recovery seizures. It's interesting to note that various medications behave differently in particular mutants, suggesting that drug reactions vary by genotype. This implies that pharmacogenetic variability in humans can be simulated using drosophila.

Diabetes and metabolic diseases

A useful model for researching diabetes and metabolic syndrome is Drosophila melanogaster. Central to this is the Drosophila Insulin-Like Peptide (DILP) system, which mirrors mammalian insulin in function and control. Elevated glucose and lipid levels in the hemolymph, the fly equivalent of blood, result from disruption of insulin-producing cells in the fly brain. This mimics the hyperglycemia and dyslipidemia observed in diabetes individuals (Miguel Sanz et al., 2023).

Cardiovascular diseases

These models aid in the investigation of potential medications for obesity, cardiovascular disease, and metabolic syndrome. Both pathological and functional cardiac conditions in drosophila and mammals have been associated with autophagic abnormalities in cardiovascular architecture and cellular dysfunction. Additionally, it has been used to model cardiomyopathies such as restrictive, hyper-trophic, and dilated cardiomyopathy, which can result in heart failure, as well as cardiac aging (Kervadec et al., 2023).

Infectious diseases

The Toll and Imd pathways in drosophila are linked to innate immune responses and apoptosis, much like mammalian immune signaling. Bacteria with LYS-type peptidoglycan in their cell walls (mostly Gram-positive bacteria) trigger the Toll pathway, whereas DAP-type peptidoglycan (mostly Gram-negative bacteria) triggers the IMD route. Following the translocation of NF-κB dimers to the nucleus, these pathways result in the over expression of AMPs that are specifically targeted to eradicate the infection (Souidi et al., 2021). The ability of flies to assess antibacterial responses is demonstrated by antibiotic research employing medications such as amoxicillin and tetracycline. Antibiotic tolerance mechanisms involving the persistence of E. coli have even been evaluated using the fruit fly model.

Genetic and functional studies

It simplifies the process of identifying and evaluating the roles of important genes and genes connected to disorders. Despite being thought of as a model organism best suited to investigating basic genetic and biological issues, flies are increasingly being employed as a powerful tool to explore the mechanisms underlying human genetic disorders. Drosophila's advanced genetic tools enable geographically and temporally controlled gain-of-function and loss-of-function investigations of the target genes. Fruit flies are extremely relevant for researching the genetic basis of human diseases, such as neurodegenerative disorders (like Parkinson's, Alzheimer's, and fragile X syndrome), cancers, diabetes, cardiovascular diseases, and infectious diseases, since they share roughly 75% of the genes that cause disease with humans (Chen et al., 2023).

Pharmacogenetics

Fruit flies (Drosophila melanogaster) have been used extensively in pharmacogenetics, the study of how genetic diversity affects medication response. Fruit flies are a potent model for investigating gene-drug interactions and pre-clinical drug discovery. Gene-drug interactions that are significant for human health are often revealed by drosophila models used to screen for anticancer, anti-epileptic and analgesic drugs (Jain et al., 2021). Similar to human neuropharmacology, fruit flies are employed to investigate the genetic underpinnings of drug-induced behavioral alterations.

Drosophila as a Model for the Circadian Clock

The genetic tractability and functional simplicity of Drosophila melanogaster have rendered it a basic model organism for unraveling the genetic, molecular, and neurological processes underlying the circadian clock. The work in drosophila uncovered the mechanism of the negative feedback loop that generates 24-hr rhythmic cycles, which is highly conserved in mammals, and identified master clock genes such as period and timeless. These have been key to understanding the evolution, mechanisms, and control of circadian rhythm (Figure 3). Many physiological and behavioral processes, such as feeding, learning, sleep, and locomotor activity, are controlled by the circadian clock in drosophila, which also coordinates cycles within the brain and other organs. Mammalian circadian biology has been impacted by drosophila findings directly through, and it is now a powerful tool for discovering fundamental principles and novel circadian regulators with far-reaching implications for human health (Asiri et al., 2024).

Figure 3: Circadian Clock Model of Drosophila.

Pleiotropic Actions of Statins on Fruit Fly Metabolism and Development

Fruit flies (Drosophila melanogaster) possess genetic mechanisms controlling cholesterol that are highly conserved with humans and therefore provide a good model to study the actions of statins on cholesterol metabolism. Statins such as simvastatin have been found to exactly replicate the pleiotropic (cholesterol-independent) benefits exhibited in humans by increasing lifespan and enhancing cardiac function in old flies. This effect is most probably resulting from alterations in protein prenylation and not cholesterol levels. Since drosophila retains the statin target HMG-CoA reductase and muscle physiology, the animal can also be employed to examine statin side effects, including those related to muscle. Different research works done on drosophila is represented in Table 1.

Table 1: Research works done on fruit flies as animal model.
TypeDrugDiseases
Panneuronal OE of Tau, (Elav-Gal4)paclitaxelAlzheimer’s disease and Parkinson’s.
Surf1BezafibrateAlzheimer’s disease.
Drosophila simulans strainCisplatin, Dacarbazine, and DaunorubicinAlzheimer’s disease and cancer.
Transient receptor potential (TRP) and PIEZO-type mechanosensitive channel components (PIEZO)Capsazepine, Yohimbine, Carvacrol, RosiglitazoneParkinson'sand Alzheimer's diseases.
C. elegansLevamisoleParkinson'sand Alzheimer's diseases.
Ras (Rasv12)Sotorasib (Lumakras) and adagrasibCancer research, cell biology.
ΦC31 recombination-mediated cassette exchange (RMCE)Blasticidin S HygromycinB G418 sulfate (geneticin)Parkinson'sand Alzheimer’s diseases, Amyotrophic Lateral Sclerosis and prion diseases.
UAS-GAL4, LexA-lexAop, QF-QUAS,Sulphonyl ureasDiabetes.
Drosophilalarval heartAtropineLarval heart function [Rhythmic control.], cardiac rate.
Wntfamily homolog wingless (wg) and the BMP family homolog decepentaplegic (dpp)Oxazole, thiazole, and thiazolidinedioneLimb formation, embryonic development, cardiomyocytes.
slowpoke, shaker, and ether-a-go-go,4-aminopyridine (4-AP)Pacemaker regulation, ion channel.
Eiger, Insulin, Wnt inhibitor of dorsal (WntD)Oxazole, Thiazole, ThiazolidinedioneInnate immunity.
Chico gene4-phenylbutyrate (PBA)Enterococcus faecalis and P. aeruginosa infections.

TECHNOLOGICAL ADVANCES AND FUTURE POTENTIAL

The application of drosophila in human disease modeling has been increasing with advances in genomics and gene editing technologies (Yoon, 2023). Fly biology research has been combined with novel resources, such as human genotype-phenotype databases, that facilitate the annotation of gene functions and the identification of novel therapeutic targets. Some recent examples are the identification of new pain receptors (e.g., the painless member of the TRP family), studies on inflammation and enteropathy with NSAID's, and the application of gut microbiota models to investigate conditions such as depression, obesity, and Crohn's disease (Swierczynski et al., 2023).

CONCLUSION

Drosophila continues to bridge the gap in information from basic research to clinical utility, from causative disease mechanism discovery to drug therapy assessment. It is a phenomenal tool for investigating the complexities of human disease and health. The perfect model organism is Drosophila melanogaster since it is genetically tractable, ethically responsible, experimentally tractable, and translationally valuable. Its numerous scientific breakthroughs have made our knowledge of biology and disease what it is today, and its future use will be thought to speed up the identification of new treatments. Drosophila as a species will undoubtedly be leading the way in biomedical innovation as research all over the world is attracted to less ethical and more sustainable methods.

REFERENCES

As published

Showing references and in-text citations exactly as published.

  1. 1.Asiri, Y. I.; Moni, S. S.; Ramar, M.; Chidambaram, K.. Advancing pain understanding and drug discovery: Insights from preclinical models and recent research findings. Pharmaceuticals. 2024;17(11):Article 1439. https://doi.org/10.3390/ph17111439DOIGOOGLE SCHOLAR
  2. 2.Chen, S.; Liao, Z.; Xu, P.. Mitochondrial control of innate immune responses. Frontiers in Immunology. 2023;14(Article 1166214.). https://doi.org/10.3389/fimmu.2023.1166214DOIGOOGLE SCHOLAR
  3. 3.Duhart, J. C.; Mosca, T. J.. Genetic regulation of central synapse formation and organization in Drosophila melanogaster. Genetics. 2022;221(3):Article iyac078. https://doi.org/10.1093/genetics/iyac078DOIGOOGLE SCHOLAR
  4. 4.Fischer, F. P.; Karge, R. A.; Koch, H.; Voigt, A.; Weber, Y. G.; Wolking, S.. The fruit fly Drosophila melanogaster as a screening model for antiseizure medications. Frontiers in Pharmacology. 2024;15:Article 1489888. https://doi.org/10.3389/fphar.2024.1489888DOIGOOGLE SCHOLAR
  5. 5.Fischer, F. P.; Karge, R. A.; Weber, Y. G.; Koch, H.; Wolking, S.; Voigt, A.. Drosophila melanogaster as a versatile model organism to study genetic epilepsies: An overview. Frontiers in Molecular Neuroscience. 2023;16(Article 1116000.). https://doi.org/10.3389/fnmol.2023.1116000DOIGOOGLE SCHOLAR
  6. 6.Jain, P.; Jain, S. K.; Jain, M.. Harnessing drug repurposing for exploration of new diseases: An insight to strategies and case studies. Current Molecular Medicine. 2021;21(2):111–132. https://doi.org/10.2174/1566524020666200619125404DOIGOOGLE SCHOLAR
  7. 7.Kashyap, S.; John, P. J.; Nirmal, N. K.. Modeling human neurodegenerative disorders in Drosophila melanogaster. Indian J. Applied and Pure Bio. 2023;38(3):1422–1433. https://doi.org/10.3390/biom12020307DOIGOOGLE SCHOLAR
  8. 8.Kervadec, A.; Kezos, J.; Ni, H.; Yu, M.; Marchant, J.; Spiering, S. et al. Multiplatform modeling of atrial fibrillation identifies phospholamban as a central regulator of cardiac rhythm. Disease Models and Mechanisms. 2023;16(7):Article dmm049962. https://doi.org/10.1242/dmm.049962DOIGOOGLE SCHOLAR
  9. 9.Kratsios, P.; Zampieri, N.; Carrillo, R.; Mizumoto, K.; Sweeney, L. B.; Philippidou, P.. Molecular and cellular mechanisms of motor circuit development. The Journal of Neuroscience. 2024;44(40):Article e1238242024. https://doi.org/10.1523/jneurosci.1238-24.2024DOIGOOGLE SCHOLAR
  10. 10.Kumar, V.; Vashishta, M.; Kong, L.; Wu, X.; Lu, J. J.; Guha, C. et al. The role of Notch, Hedgehog, and Wnt signaling pathways in the resistance of tumors to anticancer therapies. Frontiers in Cell and Developmental Biology. 2021;9:Article 650772. https://doi.org/10.3389/fcell.2021.650772DOIGOOGLE SCHOLAR
  11. 11.Lappalainen, T.; MacArthur, D. G.. From variant to function in human disease genetics. Science. 2021;373(6562):1464–1468. https://doi.org/10.1126/science.abi8207DOIGOOGLE SCHOLAR
  12. 12.Li, H.; Yang, Y.; Hong, W.; Huang, M.; Wu, M.; Zhao, X.. Applications of genome editing technology in the targeted therapy of human diseases: Mechanisms, advances and prospects. Signal Transduction and Targeted Therapy. 2020;5(1):Article 1. https://doi.org/10.1038/s41392-019-0089-yDOIGOOGLE SCHOLAR
  13. 13.Loesche, F.; Reiser, M. B.. An inexpensive, high-precision, modular spherical treadmill setup optimized for Drosophila experiments. Frontiers in Behavioral Neuroscience. 2021;15(Article 689573.). https://doi.org/10.3389/fnbeh.2021.689573DOIGOOGLE SCHOLAR
  14. 14.Madden, J. C.; Enoch, S. J.; Paini, A.; Cronin, M. T. D.. A review of in silico tools as alternatives to animal testing: Principles, resources and applications. Alternatives to Laboratory Animals. 2020;48(4):146–172. https://doi.org/10.1177/0261192920965977DOIGOOGLE SCHOLAR
  15. 15.Miguel Sanz, C.; Martinez Navarro, M.; Caballero Diaz, D.; Sanchez-Elexpuru, G.; Di Donato, V.. Toward the use of novel alternative methods in epilepsy modeling and drug discovery. Frontiers in Neurology. 2023;14(Article 1213969.). https://doi.org/10.3389/fneur.2023.1213969DOIGOOGLE SCHOLAR
  16. 16.Munnik, C.; Xaba, M. P.; Malindisa, S. T.; Russell, B. L.; Sooklal, S. A.. Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies. Frontiers in Genetics. 2022;13:Article 949241. https://doi.org/10.3389/fgene.2022.949241DOIGOOGLE SCHOLAR
  17. 17.Nainu, F.; Salim, E.; As’ad, M. F.; Chandran, D.; Dhama, K.; Rabaan, A. A. et al. Fruit fly for anticancer drug discovery and repurposing. Annals of Medicine and Surgery. 2023;85(2):337–342. https://doi.org/10.1097/ms9.0000000000000222DOIGOOGLE SCHOLAR
  18. 18.Obafemi, O. T.; Ayeleso, A. O.; Adewale, O. B.; Unuofin, J.; Ekundayo, B. E.; Ntwasa, M. et al. Animal models in biomedical research: Relevance of Drosophila melanogaster. Heliyon. 2025;11(1):Article e41605. https://doi.org/10.1016/j.heliyon.2024.e41605DOIGOOGLE SCHOLAR
  19. 19.Sarkar, S.; Das, A.. Drosophila olfaction as a model system for studying human neurological disorders. Journal of Biosciences. 2023;48(4):Article 41. https://doi.org/10.1007/s12038-023-00362-2DOIGOOGLE SCHOLAR
  20. 20.Souidi, A.; Jagla, K.. Drosophila heart as a model for cardiac development and diseases. Cells. 2021;10(11):Article 3078. https://doi.org/10.3390/cells10113078DOIGOOGLE SCHOLAR
  21. 21.Swierczynski, M.; Makaro, A.; Grochowska, A.; Salaga, M.. Pharmacological approaches to treat intestinal pain. Expert Review of Clinical Pharmacology. 2023;16(4):297–311. https://doi.org/10.1080/17512433.2023.2195626DOIGOOGLE SCHOLAR
  22. 22.Vashishat, A.; Patel, P.; Das Gupta, G.; Das Kurmi, B.. Alternatives of animal models for biomedical research: A comprehensive review of modern approaches. Stem Cell Reviews and Reports. 2024;20(4):881–899. https://doi.org/10.1007/s12015-024-10701-xDOIGOOGLE SCHOLAR
  23. 23.Verheyen, E. M.. The power of Drosophila in modeling human disease mechanisms. Disease Models and Mechanisms. 2022;15(3):Article dmm049549. https://doi.org/10.1242/dmm.049549DOIGOOGLE SCHOLAR
  24. 24.Victor Atoki, A.; Aja, P. M.; Shinkafi, T. S.; Ondari, E. N.; Adeniyi, A. I.; Fasogbon, I. V. et al. Exploring the versatility of Drosophila melanogaster as a model organism in biomedical research: A comprehensive review. Fly. 2025;19(1):Article 2420453. https://doi.org/10.1080/19336934.2024.2420453DOIGOOGLE SCHOLAR
  25. 25.Yamamoto, S.; Kanca, O.; Wangler, M. F.; Bellen, H. J.. Integrating non-mammalian model organisms in the diagnosis of rare genetic diseases in humans. Nature Reviews. Genetics. 2024;25(1):46–60. https://doi.org/10.1038/s41576-023-00633-6DOIGOOGLE SCHOLAR
  26. 26.Yamamura, R.; Ooshio, T.; Sonoshita, M.. Tiny Drosophila makes giant strides in cancer research. Cancer Science. 2021;112(2):505–514. https://doi.org/10.1111/cas.14747DOIGOOGLE SCHOLAR
  27. 27.Yoon, W. H.. Recent progress in using Drosophila as a platform for human genetic disease research. Journal of Genetic Medicine. 2023;20(2):39–45. https://doi.org/10.5734/jgm.2023.20.2.39DOIGOOGLE SCHOLAR
  28. 28.Yusuf, K.; Umar, S.; Ahmed, I.. Singapore. Animal models in cancer research. In Handbook of Animal Models and its Uses in Cancer Research. Springer Nature.. 2022;1–20. https://doi.org/10.1007/978-981-19-1282-5_17-1DOIGOOGLE SCHOLAR

Cite this article

SELECT FORMAT

Reddy, Y. M., Haranath, C., Bhargavi, D., Priya, G., Nikhila, S., Sruthi, U., Tasleem, T. S., & Veekshana, K. (2026). Fruit Flies: From Model Organism to Medical Marvel in Pharmaceutical Research. Journal of Young Pharmacists, 18(1), 39–45. https://doi.org/10.5530/jyp.20260297